KCNA3 and nervous system disorder: In all these animal models of neurological disease increased KV1.3 expression was observed on pathology-associated microglia and treatment with KV1.3 blockers resulted in reduced microglia activation and reduced inflammatory cytokine levels in the brains of the animals.